Trial Profile
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Deuruxolitinib (Primary)
- Indications Alopecia areata
- Focus Adverse reactions; Therapeutic Use
- Sponsors Concert Pharmaceuticals
- 02 Apr 2024 Planned End Date changed from 1 May 2024 to 1 Sep 2024.
- 02 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jun 2024.
- 28 Feb 2023 The protocol was amended to increase in time frame from 220 weeks to 276 weeks.